{
  "nctId": "NCT02669940",
  "briefTitle": "Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation",
  "officialTitle": "Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation - An Observational, Multi-Center Study",
  "protocolDocument": {
    "nctId": "NCT02669940",
    "filename": "Prot_001.pdf",
    "label": "Study Protocol",
    "date": "2015-06-26",
    "uploadDate": "2018-06-22T12:27",
    "size": 2640628,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02669940/document/Prot_001.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 158,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2016-04-15",
    "completionDate": "2017-07-04",
    "primaryCompletionDate": "2017-07-04",
    "firstSubmitDate": "2016-01-28",
    "firstPostDate": "2016-02-01"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\nPatients are eligible for observation in this cohort if the following applies:\n\n* Treatment-naïve or -experienced adult male or female patients with confirmed chronic hepatitis C, genotype 1, receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir ± RBV according to standard of care and in line with the current local label\n* If RBV is co-administered with paritaprevir/r - ombitasvir with or without dasabuvir, it has been prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy)\n* Patients must voluntarily sign and date informed consent prior to inclusion into the study\n\nExclusion Criteria:\n\n* Patient must not be participating or intending to participate in a concurrent interventional therapeutic trial",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "99 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-Treatment (SVR12)",
        "description": "SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels \\< 50 IU/mL 12 weeks after the last actual dose of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV.",
        "timeFrame": "12 weeks after the last actual dose of study drug"
      }
    ],
    "secondary": [
      {
        "measure": "Percentage of Participants Meeting SVR12 Non-Response Categories of Breakthrough, Failure to Suppress, and/or Relapse",
        "description": "Breakthrough is defined as at least 1 documented HCV RNA \\<50 IU/mL followed by HCV RNA ≥50 IU/mL during treatment. Failure to suppress is defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL. Relapse is defined as HCV RNA \\< 50 IU/mL at end of treatment or at the last on-treatment HCV RNA measurement followed by HCV RNA ≧ 50 IU/mL posttreatment.",
        "timeFrame": "12 weeks after last actual dose of study drug"
      },
      {
        "measure": "SVR12 Non-Response: Percentage of Participants With Breakthrough",
        "description": "Breakthrough is defined as at least 1 documented HCV RNA \\<50 IU/mL followed by HCV RNA ≥50 IU/mL during treatment.",
        "timeFrame": "12 weeks after the last actual dose of study drug"
      },
      {
        "measure": "SVR12 Non-Response: Percentage of Participants With Failure to Suppress",
        "description": "Failure to suppress is defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL.",
        "timeFrame": "12 weeks after the last actual dose of study drug"
      },
      {
        "measure": "SVR12 Non-Response: Percentage of Participants With Relapse",
        "description": "Relapse is defined as HCV RNA \\<50 IU/mL at EoT or at the last on-treatment HCV RNA measurement followed by HCV RNA ≧ 50 IU/mL posttreatment.",
        "timeFrame": "12 weeks after last actual dose of study drug"
      },
      {
        "measure": "SVR12 Non-Response: Percentage of Participants With Premature Study Drug Discontinuation With No On-Treatment Virologic Failure",
        "description": "On-treatment virologic failure included virological breakthrough and failure to suppress. Virological breakthrough was defined as at least one documented HCV RNA \\< 50 IU/mL or undetectable/negative followed by HCV RNA ≥ 50 IU/mL during treatment. Failure to suppress was defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL or positive.",
        "timeFrame": "12 weeks after last actual dose of study drug"
      },
      {
        "measure": "SVR12 Non-Response: Percentage of Participants With Missing SVR12 Data",
        "timeFrame": "12 weeks after last actual dose of study drug"
      },
      {
        "measure": "Percentage of Participants Achieving Sustained Virologic Response 24 Weeks Post-Treatment (SVR24)",
        "description": "SVR24 is defined as HCV RNA levels \\< 50 IU/mL 24 weeks after the last actual dose of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV.",
        "timeFrame": "24 weeks after last actual dose of study drug"
      },
      {
        "measure": "Percentage of Participants Achieving Virological Response at End of Treatment",
        "description": "Virologic response is defined as HCV RNA \\< 50 IU/mL.",
        "timeFrame": "From baseline until end of treatment (12 or 24 weeks after actual first dose)"
      }
    ],
    "other": [
      {
        "measure": "Percentage of Participants Achieving SVR12: Additional Analysis",
        "description": "SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels \\< 50 IU/mL or undetectable/negative 12 weeks after the last actual dose of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV.",
        "timeFrame": "12 weeks after the last actual dose of study drug"
      },
      {
        "measure": "Percentage of Participants Meeting SVR12 Non-Response Categories of Breakthrough, Failure to Suppress, and/or Relapse: Additional Analysis",
        "description": "Breakthrough is defined as at least 1 documented HCV RNA \\<50 IU/mL or undetectable/negative followed by HCV RNA ≥50 IU/mL or positive during treatment. Failure to suppress is defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL or positive. Relapse is defined as HCV RNA \\< 50 IU/mL or undetectable/negative at end of treatment or at the last on-treatment HCV RNA measurement followed by HCV RNA ≧ 50 IU/mL or positive posttreatment.",
        "timeFrame": "12 weeks after last actual dose of study drug"
      },
      {
        "measure": "SVR12 Non-Response: Percentage of Participants With Breakthrough: Additional Analysis",
        "description": "Breakthrough is defined as at least 1 documented HCV RNA \\<50 IU/mL or undetectable/negative followed by HCV RNA ≥50 IU/mL or positive during treatment.",
        "timeFrame": "12 weeks after the last actual dose of study drug"
      },
      {
        "measure": "SVR12 Non-Response: Percentage of Participants With Failure to Suppress: Additional Analysis",
        "description": "Failure to suppress is defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL or positive.",
        "timeFrame": "12 weeks after the last actual dose of study drug"
      },
      {
        "measure": "SVR12 Non-Response: Percentage of Participants With Relapse: Additional Analysis",
        "description": "Relapse is defined as HCV RNA \\< 50 IU/mL or undetectable/negative at end of treatment or at the last on-treatment HCV RNA measurement followed by HCV RNA ≧ 50 IU/mL or positive posttreatment.",
        "timeFrame": "12 weeks after last actual dose of study drug"
      },
      {
        "measure": "Percentage of Participants Achieving SVR24: Additional Analysis",
        "description": "SVR24 is defined as HCV RNA levels \\< 50 IU/mL or undetectable/negative 24 weeks after the last actual dose of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV.",
        "timeFrame": "24 weeks after last actual dose of study drug"
      },
      {
        "measure": "Percentage of Participants Achieving Virological Response at End of Treatment: Additional Analysis",
        "description": "Virologic response is defined as HCV RNA \\< 50 IU/mL or undetectable/negative.",
        "timeFrame": "From baseline until end of treatment (12 or 24 weeks after actual first dose)"
      }
    ]
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 8,
      "otherCount": 7,
      "totalCount": 16
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 83,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-21T22:34:13.153Z",
  "dataSource": "ClinicalTrials.gov API v2 - Mass Collection"
}